Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF

Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF

Background: Inflammation and oxidative stress are thought to play an important role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF) through the development of endothelial dysfunction. Myeloperoxidase (MPO) functions as a link between oxidative stress and inflammation...

Full description

Bibliographic Details
Main Authors:	Sibille Lejeune, Audrey Ginion, Nassiba Menghoum, David Vancraeynest, Agnes Pasquet, Bernhard L. Gerber, Sandrine Horman, Christophe Beauloye, Anne-Catherine Pouleur
Format:	Article
Language:	English
Published:	IMR Press 2023-02-01
Series:	Reviews in Cardiovascular Medicine
Subjects:	heart failure with preserved ejection fraction myeloperoxidase oxidative stress inflammation diabetes vascular stiffness
Online Access:	https://www.imrpress.com/journal/RCM/24/2/10.31083/j.rcm2402056

Similar Items

Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
by: Camilla Hage, et al.
Published: (2020-08-01)

Similarities and Differences Between HFmrEF and HFpEF
by: Peixin Li, et al.
Published: (2021-09-01)

Mean platelet volume: a prognostic marker in heart failure with preserved ejection fraction
by: Nassiba Menghoum, et al.
Published: (2023-12-01)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
by: Alberto Palazzuoli, et al.
Published: (2021-05-01)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
by: Manuel Martínez-Sellés, et al.
Published: (2022-05-01)

HFpEF as systemic disease, insight from a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in HFpEF patients
by: Rong Zhou, et al.
Published: (2024-03-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Obesity and HFpEF
by: Francesco Clemenza, et al.
Published: (2022-07-01)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018-01-01)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
by: Steven J. Simmonds, et al.
Published: (2020-01-01)

Characteristics, prognosis, and treatment response in HFpEF patients with high vs. normal ejection fraction
by: Jun Gu, et al.
Published: (2022-09-01)

Is excessive ventricular irregularity predictive of rehospitalization in patients with permanent AF and HFpEF?
by: Corentin Chaumont, et al.
Published: (2023-06-01)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
by: Yanhong Guo, et al.
Published: (2022-11-01)

Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
by: Liling Chen, et al.
Published: (2022-02-01)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
by: María Valero-Muñoz, et al.
Published: (2022-08-01)

Non-invasive assessment of HFpEF in mouse models: current gaps and future directions
by: María Villalba-Orero, et al.
Published: (2022-10-01)

A potential role of autophagy-mediated vascular senescence in the pathophysiology of HFpEF
by: Fernanda Sanhueza-Olivares, et al.
Published: (2022-11-01)

Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease
by: Andrea Saavedra-Alvarez, et al.
Published: (2022-12-01)

Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation
by: Linjuan Guo, et al.
Published: (2023-09-01)

The pK56M ICAM1 HFpEF risk variant and inflammatory biomarkers
by: Pedro Giro, et al.
Published: (2023-12-01)

Clinical efficacy of sacubitril/valsartan in treatment of acute STEMI complicated with HFpEF
by: Kong Can, Peng Hui
Published: (2023-06-01)

Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients
by: Valentine Robaux, et al.
Published: (2023-12-01)

Contribution of Global and Regional Longitudinal Strain for Clinical Assessment of HFpEF in Coronary and Hypertensive Patients
by: Gheorghe Stoichescu-Hogea, et al.
Published: (2021-12-01)

Focus on HFpEF in heart failure
by: Chunhui He, et al.
Published: (2022-05-01)

Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study
by: Artem Ovchinnikov, et al.
Published: (2022-07-01)

Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort
by: Sibille Lejeune, et al.
Published: (2021-02-01)

Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest
by: Alberto Palazzuoli, et al.
Published: (2023-01-01)

Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF
by: Ying Zhou, et al.
Published: (2021-09-01)

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
by: Wenchao Zhang, et al.
Published: (2021-01-01)

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
by: Dzhioeva O, et al.
Published: (2020-08-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
by: M. A. Manukyan, et al.
Published: (2021-11-01)

Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: a prospective cross‐over study
by: Jerremy Weerts, et al.
Published: (2023-12-01)

Impact of readmissions on octogenarians with heart failure with preserved ejection fraction: PURSUIT‐HFpEF registry
by: Masami Nishino, et al.
Published: (2021-06-01)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
by: David Bode, et al.
Published: (2021-01-01)

Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry
by: Jeehoon Kang, et al.
Published: (2018-03-01)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
by: Leonie Grossekettler, et al.
Published: (2020-05-01)

Left atrial conduit flow rate at baseline and during exercise: an index of impaired relaxation in HFpEF patients
by: Paolo N. Marino, et al.
Published: (2021-10-01)

Diastolic dysfunction and sex-specific progression to HFpEF: current gaps in knowledge and future directions
by: A. M. L. N. van Ommen, et al.
Published: (2022-12-01)

ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
by: Antje Schauer, et al.
Published: (2020-10-01)